Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in
patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH) to determine
the safety and tolerability of ascending single and repeated doses of HepaStem administered
to patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH)